AAAAAA
Results: 1-25/32
Authors:
PRICHEN S
PITARU S
LOKIEC F
SAVION N
Citation: S. Prichen et al., BASIC FIBROBLAST-GROWTH-FACTOR ENHANCES THE GROWTH AND EXPRESSION OF THE OSTEOGENIC PHENOTYPE OF DEXAMETHASONE-TREATED HUMAN BONE-MARROW-DERIVED BONE-LIKE CELLS IN CULTURE, Bone (New York, N.Y.), 23(2), 1998, pp. 111-117
INTERACTION BETWEEN TOPOTECAN AND CYCLOSPORINE - CLINICAL-RESULTS ANDPHARMACOKINETICS OVER 3 COURSES
Authors:
GROSS M
LOKIEC F
LEMOINE A
CASTAING D
SAMUEL D
LEVI F
MISSET JL
GOLDWASSER F
Citation: M. Gross et al., INTERACTION BETWEEN TOPOTECAN AND CYCLOSPORINE - CLINICAL-RESULTS ANDPHARMACOKINETICS OVER 3 COURSES, Annals of oncology, 9, 1998, pp. 668-668
Authors:
WASSERMAN E
MYARA A
LOKIEC F
RIOFRIO M
IMADALOU K
BLEUZEN P
SANTONI J
TRIVIN F
HERAIT P
MAHJOUBI M
ARMAND JP
MISSET JL
CVITKOVIC E
Citation: E. Wasserman et al., BILIRUBIN (BIL) AND SN-38 - PHARMACOKINETIC PHARMACODYNAMICS CORRELATION/, Annals of oncology, 9, 1998, pp. 220-220
Authors:
LOKIEC F
ARBEL R
ISAKOV J
WEINTROUB S
Citation: F. Lokiec et al., NEUROPATHIC ARTHROPATHY OF THE KNEE ASSOCIATED WITH AN INTRAARTICULARNEUROFIBROMA IN A CHILD, Journal of bone and joint surgery. British volume, 80B(3), 1998, pp. 468-470
Authors:
RIVORY LP
HAAZ MC
CANAL P
LOKIEC F
ARMAND JP
ROBERT J
Citation: Lp. Rivory et al., PHARMACOKINETIC INTERRELATIONSHIPS OF IRINOTECAN (CPT-11) AND ITS 3 MAJOR PLASMA METABOLITES IN PATIENTS ENROLLED IN PHASE-I II TRIALS/, Clinical cancer research, 3(8), 1997, pp. 1261-1266
Authors:
WASSERMAN E
MYARA A
LOKIEC F
KACI MO
GOLDWASSER F
MAGHERINI E
CVITKOVIC E
MISSET JL
Citation: E. Wasserman et al., EVIDENCE FOR ENHANCED TOXICITY TO CPT-11 IN PATIENTS WITH GILBERTS-SYNDROME - 2 CASE-REPORTS, European journal of cancer, 33, 1997, pp. 1130-1130
Authors:
SOULIE P
TRANDAFIR L
TAAMMA A
LOKIEC F
BRAIN E
DELORD JP
MITA A
VANNETZEL JM
CVITKOVIC E
MISSET JL
Citation: P. Soulie et al., SCHEDULE-DEPENDENT PACLITAXEL TOLERANCE ACTIVITY - DATA FROM A 7 DAY INFUSION PHASE-I STUDY WITH PHARMACOKINETICS IN PACLITAXEL REFRACTORY OVARIAN-CANCER/, Anti-cancer drugs, 8(8), 1997, pp. 763-766
Authors:
WASSERMAN E
MYARA A
LOKIEC F
GOLDWASSER F
TRIVIN F
MAHJOUBI M
MISSET JL
CVITKOVIC E
Citation: E. Wasserman et al., SEVERE CPT-11 TOXICITY IN PATIENTS WITH GILBERTS-SYNDROME - 2 CASE-REPORTS, Annals of oncology, 8(10), 1997, pp. 1049-1051
Authors:
ABAD S
DERAY G
LOKIEC F
HAMANI A
PETITCLERC T
JACOBS C
Citation: S. Abad et al., COMA INDUCED BY INTRAVENOUS ACYCLOVIR IN A HEMODIALYSIS PATIENT, La Presse medicale, 26(22), 1997, pp. 1050-1050
Authors:
LOKIEC F
Citation: F. Lokiec, PLASMATIC HALF-LIFE (VOL 84, PG 1083, 199 7), Bulletin du cancer, 84(12), 1997, pp. 1150-1150
Authors:
LOKIEC F
Citation: F. Lokiec, PLASMATIC HALF-LIFE, Bulletin du cancer, 84(11), 1997, pp. 1083-1084
Authors:
LOKIEC F
DUSORBIER BM
SANDERINK GJ
Citation: F. Lokiec et al., IRINOTECAN (CPT-11) METABOLITES IN HUMAN BILE AND URINE, Clinical cancer research, 2(12), 1996, pp. 1943-1949
Authors:
ILIADIS A
LAUNAYILIADIS MC
LUCAS C
FETY R
LOKIEC F
TRANCHAND B
MILANO G
Citation: A. Iliadis et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF NITROSOUREA FOTEMUSTINE - A FRENCH CANCER CENTER MULTICENTRIC STUDY, European journal of cancer, 32A(3), 1996, pp. 455-460
Authors:
LOKIEC F
SANTONI J
WEILL S
TUBIANAHULIN M
Citation: F. Lokiec et al., PHENOBARBITAL ADMINISTRATION DOES NOT AFFECT HIGH-DOSE IFOSFAMIDE PHARMACOKINETICS IN HUMANS, Anti-cancer drugs, 7(8), 1996, pp. 893-896
Authors:
VELKES S
NERUBAY J
LOKIEC F
Citation: S. Velkes et al., STRESS-FRACTURE OF THE PROXIMAL FEMUR AFTER SCREW REMOVAL, Archives of orthopaedic and trauma surgery, 115(1), 1996, pp. 61-62
Authors:
WIENTROUB S
LOKIEC F
EZRA E
KHERMOSH O
Citation: S. Wientroub et al., COMPLETE HEALING OF BONE-CYSTS IN CHILDREN BY PERCUTANEOUS BONE-MARROW GRAFTING, Journal of bone and mineral research, 11, 1996, pp. 663-663
Authors:
CANAL P
GAY C
DEZEUZE A
DOUILLARD JY
BUGAT R
BRUNET R
ADENIS A
HERAIT P
LOKIEC F
MATHIEUBOUE A
Citation: P. Canal et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER, Journal of clinical oncology, 14(10), 1996, pp. 2688-2695
Authors:
LOKIEC F
EZRA E
KHERMOSH O
WIENTROUB S
Citation: F. Lokiec et al., SIMPLE BONE-CYSTS TREATED BY PERCUTANEOUS AUTOLOGOUS MARROW GRAFTING - A PRELIMINARY-REPORT, Journal of bone and joint surgery. British volume, 78B(6), 1996, pp. 934-937
Authors:
MARTIN C
VIVIAND X
ALAYA M
LOKIEC F
ENNABLI K
SAID R
PECKING M
Citation: C. Martin et al., PENETRATION OF CEFTRIAXONE (1 OR 2 GRAMS INTRAVENOUSLY) INTO MEDIASTINAL AND CARDIAC TISSUES IN HUMANS, Antimicrobial agents and chemotherapy, 40(3), 1996, pp. 812-815
Authors:
TUBIANAHULIN M
CVITKOVIC F
LOKIEC F
BOZEC L
GOUPIL A
JANVIER M
TURPIN F
ROUESSE J
Citation: M. Tubianahulin et al., LOW EFFICACY OF 1 HOUR INFUSION HIGH-DOSE IFOSFAMIDE (IFO) IN PREVIOUSLY PRETREATED SARCOMA, European journal of cancer, 31A, 1995, pp. 871-871
Authors:
LOKIEC F
CANAL P
MATHIEUBOUE A
ARMAND JP
BUGAT R
Citation: F. Lokiec et al., CPT-11 METABOLISM IN BLOOD, BILE AND URINE IN CANCER-PATIENTS, European journal of cancer, 31A, 1995, pp. 947-947
Authors:
LOKIEC F
SANTONI J
WEILL S
TUBIANAHULIN M
Citation: F. Lokiec et al., PHENOBARBITAL (PB) INFLUENCE ON IFOSFAMIDE (IF) PHARMACOKINETICS (PK)IN SARCOMA PATIENTS, European journal of cancer, 31A, 1995, pp. 948-948
Authors:
VIVIAND X
ALAYA M
LOKIEC F
ENNABLI K
SAID R
PECKING M
MARTIN C
Citation: X. Viviand et al., PENETRATION OF CEFTRIAXONE INTO MEDIASTIN AL AND CARDIAC TISSUES IN HUMANS, Pathologie et biologie, 43(4), 1995, pp. 364-369
Authors:
LOKIEC F
CANAL P
GAY C
CHATELUT E
ARMAND JP
ROCHE H
BUGAT R
GONCALVES E
MATHIEUBOUE A
Citation: F. Lokiec et al., PHARMACOKINETICS OF IRINOTECAN AND ITS METABOLITES IN HUMAN BLOOD, BILE, AND URINE, Cancer chemotherapy and pharmacology, 36(1), 1995, pp. 79-82
Authors:
LOKIEC F
Citation: F. Lokiec, PHARMACOKINETIC CHARACTERISTICS OF TAXOIDS, La Semaine des hopitaux de Paris, 71(23-24), 1995, pp. 687-691